Extended TEA deadlines
This article was originally published in The Rose Sheet
Executive Summary
FDA grants 90-day extension, until Aug. 21, for submitting for priority review "time and extent" applications based on previously filed citizen petitions to include foreign-marketed ingredients in OTC monographs. Agency's June 20 letters to various firms recognize several factors limiting companies' ability to complete applications by original May 23 deadline, including age of original petitions, foreign locations of parent companies. Merck KGaA, BASF, P&G, European-American Phytomedicines Coalition among petitioners notified about extension; ingredients at issue include sunscreens, antiseptics, ginger, valerian. Agency originally had directed petitions be converted to TEAs within 120 days of Jan. 23 final reg on "material time, material extent" criteria (1"The Rose Sheet" May 6, 2002, In Brief)...
You may also be interested in...
Sunscreen petitions
FDA will "give priority" to reviews of time and extent applications (TEAs) submitted by firms that previously petitioned agency to include specific foreign-marketed ingredients in sunscreen monograph, FDA reiterates in six letters to ingredient suppliers and their counsel. As outlined in Jan. 23 final reg, citizen petitions must be converted to TEAs "within 120 days" of rule's publication (1"The Rose Sheet" Jan. 28, 2002, p. 9). Letters to Ciba Specialty Chemicals, EM Industries, BASF counsel and Haarmann & Reimer counsel, dated from April 19 through April 25, advise firms that agency does not "intend to take further action" on firms' respective petitions...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.